ConductScience.org, home

Disease · HP_0000238

Hydrocephalus

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Hydrocephalus. Diseases, record HP_0000238. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000238

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Hydrocephalus
Open Targets ID
HP_0000238
Other names
Hydrocephaly, Nonsyndromal hydrocephalus, Too much cerebrospinal fluid in the brain
Highest stage of its drugs
Approval, for 1 of its 5 drugs, from TTD

Source Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ISOSORBIDE MONONITRATECHEMBL1311Small moleculeApprovalTTD100Drugs and targets
DEXMEDETOMIDINECHEMBL778Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
ISOFLURANECHEMBL1256Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
ALTEPLASECHEMBL1201593EnzymePhase 1/2ClinicalTrials.gov110Drugs and targets
FIBRINOGEN, HUMANCHEMBL2109072UnknownClinicalTrials.gov111Drugs and targets

Targets33

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRA2AAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 3https://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 3https://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 3https://conductscience.org/library/genes/152Drugs and targets
FGAFibrinogen1Fibrinogen exogenous proteinUnknownhttps://conductscience.org/library/genes/2243Drugs and targets
FGBFibrinogen1Fibrinogen exogenous proteinUnknownhttps://conductscience.org/library/genes/2244Drugs and targets
FGGFibrinogen1Fibrinogen exogenous proteinUnknownhttps://conductscience.org/library/genes/2266Drugs and targets
GABRA1GABA-A receptor; anion channel1GABA-A receptor; anion channel positive allosteric modulatorPhase 3https://conductscience.org/library/genes/2554Drugs and targets
GABRA2GABA-A receptor; anion channel1GABA-A receptor; anion channel positive allosteric modulatorPhase 3https://conductscience.org/library/genes/2555Drugs and targets
GABRA3GABA-A receptor; anion channel1GABA-A receptor; anion channel positive allosteric modulatorPhase 3https://conductscience.org/library/genes/2556Drugs and targets
GABRA4GABA-A receptor; anion channel1GABA-A receptor; anion channel positive allosteric modulatorPhase 3https://conductscience.org/library/genes/2557Drugs and targets

1 to 10 of 33

See all 33 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT02512809Isoflurane-induced Neuroinflammation in Children With HydrocephalusPhase 3252018-12-13Toxicity, HydrocephalusDEXMEDETOMIDINE, ISOFLURANEIts record names the diseaseClinicalTrials.gov
NCT05717335Observational Pilot Study With TachoSil as a Ventricular Sealant20Intraventricular NeoplasmFIBRINOGEN, HUMANIts record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
34916315RESULT1PubMed
34499261RESULT1PubMed
33538867RESULT1PubMed
31058968RESULT1PubMed
29232819RESULT1PubMed
28751035RESULT1PubMed
28729143RESULT1PubMed
28529027RESULT1PubMed
28083041RESULT1PubMed
27813467RESULT1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000238

GET https://conductscience.org/api/diseases/v1/HP_0000238/targets?page=2